Hearing loss in osteogenesis imperfecta: characteristics and treatment considerations
- PMID: 22567374
- PMCID: PMC3335494
- DOI: 10.4061/2011/983942
Hearing loss in osteogenesis imperfecta: characteristics and treatment considerations
Abstract
Osteogenesis imperfecta (OI) is the most common heritable disorder of connective tissue. It is associated with fractures following relatively minor injury, blue sclerae, dentinogenesis imperfecta, increased joint mobility, short stature, and hearing loss. Structures in the otic capsule and inner ear share in the histologic features common to other skeletal tissues. OI is due to mutations involving several genes, the most commonly involved are the COL1A1 or COL1A2 genes which are responsible for the synthesis of the proalpha-1 and proalpha-2 polypeptide chains that form the type I collagen triple helix. A genotype/phenotype relationship to hearing loss has not been established in OI. Hearing loss is commonly found in OI with prevalence rates ranging from 50 to 92% in some studies. Hearing loss in OI may be conductive, mixed, or sensorineural and is more common by the second or third decade. Treatment options such as hearing aids, stapes surgery, and cochlear implants are discussed.
Similar articles
-
COL1A1/2 Osteogenesis Imperfecta.2005 Jan 28 [updated 2024 Mar 14]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. 2005 Jan 28 [updated 2024 Mar 14]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024. PMID: 20301472 Free Books & Documents. Review.
-
Osteogenesis Imperfecta: the audiological phenotype lacks correlation with the genotype.Orphanet J Rare Dis. 2011 Dec 29;6:88. doi: 10.1186/1750-1172-6-88. Orphanet J Rare Dis. 2011. PMID: 22206639 Free PMC article.
-
Clinical characteristics and the identification of novel mutations of COL1A1 and COL1A2 in 61 Chinese patients with osteogenesis imperfecta.Mol Med Rep. 2016 Nov;14(5):4918-4926. doi: 10.3892/mmr.2016.5835. Epub 2016 Oct 12. Mol Med Rep. 2016. PMID: 27748872
-
Lack of correlation between the type of COL1A1 or COL1A2 mutation and hearing loss in osteogenesis imperfecta patients.Hum Mutat. 2004 Aug;24(2):147-54. doi: 10.1002/humu.20071. Hum Mutat. 2004. PMID: 15241796
-
Osteogenesis imperfecta:epidemiology and pathophysiology.Curr Osteoporos Rep. 2007 Sep;5(3):91-7. doi: 10.1007/s11914-007-0023-z. Curr Osteoporos Rep. 2007. PMID: 17925189 Review.
Cited by
-
A Consolidated Understanding of the Contribution of Redox Dysregulation in the Development of Hearing Impairment.Antioxidants (Basel). 2024 May 13;13(5):598. doi: 10.3390/antiox13050598. Antioxidants (Basel). 2024. PMID: 38790703 Free PMC article. Review.
-
A homozygous SP7/OSX mutation causes osteogenesis and dentinogenesis imperfecta with craniofacial anomalies.JBMR Plus. 2024 Mar 4;8(5):ziae026. doi: 10.1093/jbmrpl/ziae026. eCollection 2024 May. JBMR Plus. 2024. PMID: 38562913 Free PMC article.
-
Medical Care Use Among Patients with Monogenic Osteoporosis Due to Rare Variants in LRP5, PLS3, or WNT1.Calcif Tissue Int. 2023 Aug;113(2):186-194. doi: 10.1007/s00223-023-01101-3. Epub 2023 Jun 6. Calcif Tissue Int. 2023. PMID: 37277619 Free PMC article.
-
Treatments for hearing loss in osteogenesis imperfecta: a systematic review and meta-analysis on their efficacy.Sci Rep. 2022 Oct 12;12(1):17125. doi: 10.1038/s41598-022-20169-9. Sci Rep. 2022. PMID: 36224204 Free PMC article.
-
Prevention of Hypomineralization In Auditory Ossicles of Vitamin D Receptor (Vdr) Deficient Mice.Front Endocrinol (Lausanne). 2022 Jun 6;13:901265. doi: 10.3389/fendo.2022.901265. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35733772 Free PMC article.
References
-
- McKusick VA. Heritable disorders of connective tissue. V. Osteogenesis imperfecta. Journal of Chronic Diseases. 1956;3(2):180–202. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
